Main Menu

REASURE

A phase II, open label study of biomarkers to assess response in patients with metastatic castration-resistant prostate cancer treated with radium-223.

Disease site: Prostate cancer

Treatment modality: Radiopharmaceutical, systemic therapy

Status: In follow-up

Trial details

REASURE is a phase II, multicentre, randomised trial of radium-223 incorporating diffusion-weighted MRI (DW-MRI) and PET imaging with collection of blood, urine and bone marrow samples. REASURE aims to identify potential markers of response to treatment with radium-223 in patients with castration-resistant prostate cancer with bone metastases.

38 patients will be recruited from four UK sites over 18 months. Patients will be randomised to receive a monthly radium-223 injection at a dose of either 50 kBq/kg or 80 kBq/kg for up to 6 months. Patients will be followed up every 4 months for 1 year after their last treatment of radium-223.

Further information

Chief Investigator: Dr Chris Parker, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Dr Emma Hall

Trial management contact: [email protected]

ISRCTN: 17805587

Sponsor: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Funding: Bayer HealthCare Pharmaceuticals Inc.

Further information including recruitment progress is available from the UKCRN portfolio.

The plain English summary is available from Cancer Research UK.

Publications and presentations

There have been no presentations or publications to date.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

We use cookies to ensure that we give you the best experience on our website. By continuing to use this website, you are agreeing to our use of cookies on your device as described in our cookie policy. You can change your cookie settings at any time but parts of our site will not function correctly without them.